{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:28:02Z","timestamp":1793744882558,"version":"4.6.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.gore.2026.102194","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:27:32Z","timestamp":1787239652000},"page":"102194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Serous borderline tumor progressing to low-grade serous carcinoma after 35\u00a0years: a case of extended latency with molecular evidence of clonal relationship"],"prefix":"10.1016","volume":"67","author":[{"given":"Emily A.","family":"Towery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Kolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.gore.2026.102194_bb0005","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000000693","article-title":"Low-grade serous carcinoma of the ovary","volume":"40","author":"Ahn","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0010","article-title":"HER2\/neu expression in low-grade serous ovarian carcinoma: a pilot two-center retrospective study","volume":"15","author":"Badlaeva","year":"2026","journal-title":"J. Clin. Microbiol."},{"issue":"25","key":"10.1016\/j.gore.2026.102194_bb0015","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO-25-00112","article-title":"Efficacy and safety of Avutometinib \u00b1 Defactinib in recurrent low-grade serous ovarian Cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201","volume":"43","author":"Banerjee","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102194_bb0020","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s40265-025-02215-8","article-title":"Avutometinib and Defactinib: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.gore.2026.102194_bb0025","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1097\/PAS.0000000000001325","article-title":"Clinicopathologic and molecular features of paired cases of Metachronous ovarian serous borderline tumor and subsequent serous carcinoma","volume":"43","author":"Chui","year":"2019","journal-title":"American Journal of Surgical Pathology."},{"issue":"13","key":"10.1016\/j.gore.2026.102194_bb0030","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.18632\/oncotarget.28001","article-title":"Correction: BRAFV600E-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma","volume":"12","author":"Chui","year":"2021","journal-title":"Oncotarget"},{"issue":"16 _suppl","key":"10.1016\/j.gore.2026.102194_bb0035","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/JCO.2022.40.16_suppl.5522","article-title":"A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2026.102194_bb0040","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s10637-015-0297-4","article-title":"Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation","volume":"33","author":"Combe","year":"2015","journal-title":"Invest. New Drugs"},{"issue":"1","key":"10.1016\/j.gore.2026.102194_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102194_bb0050","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.gore.2026.102194_bb0055","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.ygyno.2026.02.023","volume":"208","author":"Fader","year":"2026","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102194_bb0060","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ygyno.2009.03.001","article-title":"Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant","volume":"114","author":"Gershenson","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0065","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2026.102194_bb0070","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous Cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0075","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","article-title":"The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes","volume":"165","author":"Gershenson","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"10324","key":"10.1016\/j.gore.2026.102194_bb0080","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(21)02175-9","article-title":"Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): an international, randomised, open-label, multicentre, phase 2\/3 trial","volume":"399","author":"Gershenson","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.gore.2026.102194_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ajo.13105","article-title":"Low-grade serous ovarian carcinoma: a comprehensive literature review","volume":"60","author":"Goulding","year":"2020","journal-title":"Aust. N. Z. J. Obstet. Gynaecol."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0090","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO study group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"7","key":"10.1016\/j.gore.2026.102194_bb0095","first-page":"650","article-title":"Low-grade serous carcinoma of the ovary","volume":"30","author":"Grisham","year":"2016","journal-title":"Oncology"},{"issue":"9","key":"10.1016\/j.gore.2026.102194_bb0100","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1136\/ijgc-2023-004610","article-title":"Low-grade serous ovarian cancer: expert consensus report on the state of the science","volume":"33","author":"Grisham","year":"2023","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"11","key":"10.1016\/j.gore.2026.102194_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005919","article-title":"GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator\u2019s choice of treatment in patients with recurrent low grade serous ovarian cancer","volume":"35","author":"Grisham","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.gore.2026.102194_bb0110","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ymeth.2012.09.012","article-title":"Droplet digital\u2122 PCR quantitation of HER2 expression in FFPE breast cancer samples","volume":"59","author":"Heredia","year":"2013","journal-title":"Methods"},{"issue":"8","key":"10.1016\/j.gore.2026.102194_bb0115","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","article-title":"Differences in tumor type in low-stage versus high-stage ovarian carcinomas","volume":"29","author":"K\u00f6bel","year":"2010","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"20","key":"10.1016\/j.gore.2026.102194_bb0125","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1158\/1078-0432.CCR-21-4183","article-title":"MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.gore.2026.102194_bb0130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00428-023-03564-z","article-title":"KRAS mutation in primary ovarian serous borderline tumors correlates with tumor recurrence","volume":"483","author":"McHenry","year":"2023","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.gore.2026.102194_bb0135","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/ERC-21-0191","article-title":"New therapeutic opportunities for women with low-grade serous ovarian cancer","volume":"29","author":"Moujaber","year":"2022","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.gore.2026.102194_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.103019","article-title":"Advances in treatment strategies for low-grade serous ovarian cancer","volume":"140","author":"Musacchio","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.gore.2026.102194_bb0145","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/PGP.0000000000001059","article-title":"HER2 status in low-grade serous ovarian tumors","volume":"44","author":"N\u011bmejcov\u00e1","year":"2025","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"2","key":"10.1016\/j.gore.2026.102194_bb0150","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/cup.14352","article-title":"A novel method to assess copy number variation in melanoma: droplet digital PCR for precise quantitation of the RREB1 gene in formalin-fixed, paraffin-embedded melanocytic neoplasms, a proof-of-concept study","volume":"50","author":"O\u2019Hern","year":"2023","journal-title":"J. Cutan. Pathol."},{"issue":"5","key":"10.1016\/j.gore.2026.102194_bb0155","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s40291-017-0278-8","article-title":"Current and emerging applications of droplet digital PCR in oncology","volume":"21","author":"Olmedillas-L\u00f3pez","year":"2017","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.gore.2026.102194_bb0160","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.humpath.2018.06.018","article-title":"Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics","volume":"80","author":"Prat","year":"2018","journal-title":"Hum. Pathol."},{"issue":"7","key":"10.1016\/j.gore.2026.102194_bb0165","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with Dabrafenib plus Trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.gore.2026.102194_bb0170","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1200\/JCO.20.00762","article-title":"Dabrafenib and Trametinib in patients with tumors with BRAFV600E mutations: results of the NCI-MATCH trial subprotocol H","volume":"38","author":"Salama","year":"2020","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.gore.2026.102194_bb0175","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12032-025-03032-5","article-title":"Prevalence, detection, and clinical implications of BRAF V600E and NRAS Q61R mutations in multiple myeloma BM-FFPE tissues using digital droplet PCR","volume":"42","author":"Sharma","year":"2025","journal-title":"Med. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0180","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2007.01.030","article-title":"Comparison of the clinical behavior of newly diagnosed stages II\u2013IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma","volume":"105","author":"Shvartsman","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.gore.2026.102194_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00004347-199801000-00001","article-title":"Tumor recurrence in stage I ovarian serous neoplasms of low malignant potential","volume":"17","author":"Silva","year":"1998","journal-title":"Int J of Gyn Path."},{"issue":"2","key":"10.1016\/j.gore.2026.102194_bb0190","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/01.pas.0000146025.91953.8d","article-title":"Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with Immunohistochemical correlation","volume":"29","author":"Singer","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0195","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO-25-01348","article-title":"Phase II trial of Ribociclib plus Letrozole in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum: a GOG partners trial (GOG 3026)","volume":"44","author":"Slomovitz","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.gore.2026.102194_bb0200","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","article-title":"The RAS-MEK-ERK pathway in low-grade serous ovarian cancer","volume":"200","author":"Stover","year":"2025","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0205","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2019.06.011","article-title":"PARAGON: a phase II study of anastrozole in patients with estrogen receptor-positive recurrent\/metastatic low-grade ovarian cancers and serous borderline ovarian tumors","volume":"154","author":"Tang","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2026.102194_bb0210","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/his.13651","article-title":"BRAFV600E mutations and immunohistochemical expression of VE1 protein in low-grade serous neoplasms of the ovary","volume":"73","author":"Turashvili","year":"2018","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.gore.2026.102194_bb0215","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, Clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"Vang","year":"2009","journal-title":"Adv Anat Pathol"},{"issue":"6","key":"10.1016\/j.gore.2026.102194_bb0220","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/PAS.0000000000000824","article-title":"Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas: a population-based Clinicopathologic study of 942 cases","volume":"41","author":"Vang","year":"2017","journal-title":"American Journal of Surgical Pathology."},{"key":"10.1016\/j.gore.2026.102194_bb0225","series-title":"Female Genital Tumours","article-title":"Serous borderline tumour of the ovary","volume":"4","author":"Vang","year":"2020"},{"issue":"4","key":"10.1016\/j.gore.2026.102194_bb0230","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.2353\/ajpath.2010.100212","article-title":"BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas","volume":"177","author":"Wong","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.gore.2026.102194_bb0235","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s40257-017-0320-y","article-title":"Combinatorial therapies in melanoma: MAPK inhibitors and beyond","volume":"19","author":"Zhou","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.gore.2026.102194_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102497","article-title":"Low grade serous ovarian cancer \u2013 a rare disease with increasing therapeutic options","volume":"112","author":"Zwimpfer","year":"2023","journal-title":"Cancer Treat. Rev."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578926001748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:01:45Z","timestamp":1793743305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578926001748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S2352578926001748"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2026.102194","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serous borderline tumor progressing to low-grade serous carcinoma after 35\u00a0years: a case of extended latency with molecular evidence of clonal relationship","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2026.102194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102194"}}